10:53 AM
Aug 29, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Cervical cancer; skin cancer

Mouse studies suggest a vaccine based on a nanoparticle-HpV16gp2 peptide conjugate could help treat human papillomavirus (HPV)-associated cancers. The conjugate consists of nanoparticles with a polypropylene sulfide core and HpV16gp2 peptides linked to their surfaces via disulfide bonds. In a mouse model of HPV-positive cervical cancer, vaccination with the conjugate decreased tumor size and increased tumor levels of infiltrating CD8+ T cells and survival compared...

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >